Streamline Your Market Entry In Asia
Fast Track Registration for US and European New and Orphan Drugs in Macau, Entering the Asian Market
- Quick 30-90 Day Registration in Macau
- 100% Registration Success Rate
- No Additional Clinical Trials
- Zero Additional Investments
- 40 New Drugs Registered Last Year Alone
Expanding Access, Enhancing Capabilities
- Broad Distribution Network: After registration, all drugs become eligible for distribution across 44 major hospitals in the Guangdong Great Bay Area, Hainan, and Tianjin, serving over 120 million people.
- Reaching Far and Wide: Our extensive network ensures medications are swiftly available to a vast patient base, opening access to an additional 1.2 billion people in Northern China. Patients can travel to these hospitals for critical treatments.
- Critical Care Solutions: Addressing Urgent and Rare Medical Needs; Our pediatric orphan drugs and clinically urgent medications are now accessible directly to top hospitals in Beijing, Shanghai, Tianjin, Chongqing, and Hainan through a special program. These hospitals handle 50% of China’s rare disease cases, ensuring patients across the nation who can afford the treatment receive the necessary care without national registration. Extensive media coverage ensures that all patients in need receive timely medical assistance.
Accelerate access to treatment with Fast Track Registration in Macau for drugs addressing unmet medical needs. Our streamlined process offers US orphan drug manufacturers a swift market entry in China, allowing for quick recovery of their development investments.